Introduction
Studies of human cancer genomes have revealed numerous genetic alterations at the structural and sequence levels. By the time a cancer is diagnosed, it often comprises millions to billions of cells carrying genetic alterations that initiated malignant transformation and many others acquired along the way. Therefore, the contribution of each genetic alteration to cancer varies substantially. Some genetic alterations are strong and causal 'drivers' that confer selective growth advantages to cancer cells; others are weaker but important 'contributors' to the development of cancer; however, most are incidental 'passengers' that have been accumulated by chance during the cancer's life history (Chin and Gray, 2008) . The key challenge in cancer research is to distinguish the drivers and contributors from the passengers. Assessing the contribution of individual alterations to cancer in genetically engineered mice has proven to be the gold standard for establishing their causality in cancer (Frese and Tuveson, 2007) , and is essential for the development of cancer therapeutics.
Studies during the past few years have demonstrated that microRNAs (miRNAs), a class of small non-coding RNAs, play important roles in human cancers (Croce, 2009) . MiRNAs are endogenously encoded-single stranded RNAs of B22 nucleotides (nts) in length that bind to their target mRNAs and regulate their translation and stability (Ambros, 2004; Bartel, 2004; Bushati and Cohen, 2007) . Despite the demonstrated importance of miRNAs, determining miRNA targets has been a major obstacle . Many bioinformatic algorithms were developed to predict miRNA target genes, mainly based on seed pairing and evolutionary conservation (Rajewsky, 2006) . However, these algorithms typically predict hundreds to thousands of target genes for each miRNA, and different algorithms often produce divergent results. Moreover, these algorithms sometimes fail to predict the most biologically important miRNA targets . To overcome this problem, two groups recently developed methods to experimentally identify direct miRNA-target mRNA interactions: HITS-CLIP (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation) and PAR-CLIP (Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation) (Chi et al, 2009; Hafner et al, 2010) . These new methods hold the promise to identify miRNA binding sites in almost any cells and have the potential to revolutionize miRNA research, in the same way that chromatin immunoprecipitation (ChIP) did to transcription factor research, but their utility still awaits validation in animal models with gain-and lossof-function mutations for individual miRNAs.
Gene expression profiling of human cancer cells has revealed specific miRNA expression signatures in many human cancers (Croce, 2009) . However, the development of miRNAbased therapeutics has lagged behind, largely due to the lack of in-depth understanding of function and molecular mechanism of miRNAs in carcinogenesis. We attempt to address this issue through the analysis of miR-17B92 in the context of lymphomagenesis. MiR-17B92 is the first miRNA gene implicated in cancer and encodes for six distinct miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92) (Mendell, 2008) . These miRNAs fall into four miRNA families (miR-17, miR-18, miR-19 , and miR-92 families), with members in each family sharing the same seed sequence. The genomic region encoding human miR-17B92 is frequently amplified in lymphoma, leukemia, and solid tissue cancers, and the encoded miRNAs are highly expressed in these cancer cells (Mendell, 2008) . Previous studies showed that miR-17B92 overexpression accelerated carcinogenesis initiated by other oncogenic mutations, such as Myc and Notch activation or Rb family deletion (He et al, 2005; Mavrakis et al, 2010; Conkrite et al, 2011) . These results established miR-17B92 as an important contributor to cancer, but it remains unclear whether elevated miR-17B92 expression per se is sufficient to drive carcinogenesis. The answer to this question will determine whether targeting miR-17B92 miRNAs or their downstream pathways has any therapeutic value.
In addition to gene amplification, miR-17B92 expression can be deregulated by other mechanisms. Myc, one of the most common and potent oncogenes (Dang, 2012) , activates miR-17B92 expression by directly binding to its genomic locus (O'Donnell et al, 2005) . Myc overexpression is the defining feature of Burkitt lymphoma, a disease state characterized by Myc translocation to the immunoglobulin (Ig) locus (Klapproth and Wirth, 2010) . A recent study of Burkitt lymphoma patient biopsies found drastic miR-17B92 overexpression in all the 28 cases examined (Schmitz et al, 2012) , confirming that activation of the Myc-miR-17B92 axis is a ubiquitous feature of this malignancy. Another study showed that deletion of miR-17B92 in established Myc-driven lymphoma cell lines slowed down their growth in tissue culture and in immunodeficient hosts, suggesting that miR-17B92 contributes to the optimal growth of those cancer cell lines (Mu et al, 2009 ). Established cancer cell lines differ from primary cancers in that the former can survive and proliferate in the absence of their natural tumour microenvironment, probably enabled by additional genetic alterations obtained during the tissue culture process. While the study of cancer cell lines is largely responsible for the early progress in cancer research, recent studies suggested that many of those initial observations need to be re-evaluated in autochthonous tumour models (Frese and Tuveson, 2007) . Therefore, it remains unclear how critical miR-17B92 is in the development of autochthonous lymphomas driven by Myc.
Here we address these issues directly by generating (1) mice with B cell-specific transgenic miR-17B92 expression, and (2) mice with deletion of the miR-17B92 gene in a Myc transgenic Burkitt lymphoma model, and then monitoring lymphoma development in the resulting mice over their lifespan. Furthermore, we experimentally identified miR-17B92 target genes in B cells by PAR-CLIP, validated select target genes in miR-17B92 transgenic B cells, and explored the possibility of targeting miR-17B92 downstream pathways to treat miR-17B92-driven cancers.
Results

B cell-specific miR-17B92 transgenic mice develop lymphomas
We have previously created a miR-17B92 transgenic allele (termed miR-17B92 Tg) by homologous recombination into the Rosa26 locus. The expression of this transgene can be turned on conditionally by Cre recombinase (Xiao et al, 2008) . To directly test the role of elevated miR-17B92 expression in B cell lymphomagenesis, we generated miR-17B92 Tg/Tg;CD19Cre mice (termed TG mice hereafter) in which the miR-17B92 transgene is turned on specifically in the B-cell lineage. We detected a 3-4-fold increase in miR-17B92 expression in TG B cells ( Figure 1A ). This level of overexpression is relatively modest compared to the drastic increase (5-30-fold) that is routinely seen for miR-17B92 in human lymphomas (He et al, 2005; Schmitz et al, 2012) . Analysis of B-cell development in the bone marrow did not reveal any significant alterations. In the spleen of TG mice, we observed an expansion of CD19
-like cells, which are present mainly in the peritoneal cavity of wild-type mice, as well as a slight increase in the total B-cell number at the age of 2-4 months ( Figure 1B and Supplementary Figure S1A ). We monitored a cohort of 104 TG and 69 littermate control mice for 2 years for lymphoma development. As shown in Figure 1C , all TG mice died during this period, with an average lifespan of 40 weeks. Macroscopic examination of TG mice, sacrificed when they were sick, revealed splenomegaly and lymphadenopathy, in some cases accompanied by tumours in extranodal tissue compartments such as liver and skin ( Figure 1D ). Clonal expansion of B cells was observed in 24 of 30 sick TG mice analysed ( Figure 1E and Supplementary Table S1 ). We performed histological and immunohistochemical analyses of involved organs from the 24 mice with clonal B cell expansion (Figure 2 and  Supplementary Figure S2, Supplementary Table S1 ). Of these 24, 12 mice developed diffuse large B-cell lymphoma (DLBCL), characterized by sheets of large-to-intermediatesized, transformed-appearing lymphoid cells with numerous mitotic figures and a moderate-to-high proliferative rate as assessed by Ki-67 staining. Six mice showed lymphoid proliferations characterized by admixed centrocytic (cleaved)-and centroblastic (non-cleaved)-appearing lymphocytes, with a low-to-moderate proliferative rate as assessed by Ki-67 staining, forming a variably nodular pattern; these mice were diagnosed with follicular lymphoma (FL). One mouse showed proliferation characterized by CD138 þ plasmablastic-appearing cells with numerous mitoses and a high Ki-67 positivity rate; these features are characteristic of anaplastic plasmacytoma (AP). Two mice had lymphoid proliferations that were categorized as small B-cell lymphoma (SBL). Among the other four mice, one had clonal B cell lymphoid hyperplasia in the peritoneal cavity, one had aggressive B-cell lymphoma similar to Burkitt or high-grade mucosaassociated lymphoid tissue (MALT) lymphoma, and the other two mice had lymphomas whose histologic types were not determined (Figure 2 , Supplementary Figure S2 , and Supplementary Table S1 ). In all transplantable cases, the primary and secondary lymphoma cells exhibited identical immunophenotypes and clonal bands of the IgH locus (Supplementary Figure S1B and C). DLBCL, FL, and AP are thought to originate from germinal centre (GC) or post-GC B cells. For the 18 cases falling into these three categories, we performed immunohistochemical (IHC) analyses of Bcl6 and IRF4 expression, as well as PNA-binding ability (Supplementary Figure S2B and Supplementary Table S1 ). In addition, we expanded 6 cases of lymphomas (5 DLBCL and 1 AP) by transplanting into Rag1 À / À mice and purifying lymphomas cells from the recipient mice, and analysed their expression of Bcl6 and IRF4 protein, as well as V gene mutation status ( Figure 2B and Supplementary Table S2 ). Consistent with their classification as DLBCL, FL, and AP, 13 of these 18 cases are positive in IHC for Bcl6, a signature transcription factor of GC B cells. Among the 5 IHC Bcl6-negative cases, 2 cases (no. 22 and no. 16) are positive in western blot. This discrepancy between IHC and western blot is probably due to the limited sensitivity of Bcl6 IHC (Cattoretti et al, 2005) . The expression of IRF4, which denotes B-cell maturation toward plasma cells during late GC B-cell differentiation (De Silva et al, 2012) , ranged from negative, dim-positive, to positive ( Figure 2B and Supplementary Figure S2B , Supplementary Table S1 ), suggesting that lymphomas developed in TG mice are heterogeneous in nature, and that some of them originated from late-stage GC B cells or plasmablasts. Only two cases are positive for PNA binding, which is characteristic of GC B cells. The inability of other lymphomas to bind to PNA may be due to constitutive PI3K signalling in these cells ( Figure 8D ), similar to that reported in a recent study of a new Burkitt lymphoma mouse model that combines constitutive Myc expression and PI3K signalling, in which GC B cell-derived lymphoma cells are also PNA-negative (Sander et al, 2012) . Among all the six cases analysed, only one case (no. 1962) contains significant amount of mutations in their V genes (Supplementary Table S2 ). While most human DLBCL, FL and AP contain somatic mutations in their V genes, our result may reflect the difference between human lymphomas and lymphomas developed in genetically engineered mice, as reported in a recent study of a mouse model of DLBCL lymphomas driven by constitutive NFkB activation and Blimp1 deletion (Calado et al, 2010) . Taken together, these results showed that elevated miR-17B92 expression alone is sufficient to drive lymphomagenesis in mice with a marked preponderance of GC and post-GC B-cell-derived lymphomas. 
Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17B92
To evaluate the role of miR-17B92 during the development of autochthonous lymphomas driven by Myc, we generated l-Myc mice carrying conditional miR-17B92 knockout alleles (miR fl/fl ) under the control of CD19Cre (termed Myc;miR fl/fl ; CD19Cre mice hereafter) (Rickert et al, 1997; Kovalchuk et al, 2000; Ventura et al, 2008) . l-Myc mice express a c-Myc transgene under the control of the B cell-specific l light chain regulatory sequence. These mice develop monoclonal tumours recapitulating features of human Burkitt lymphoma (Kovalchuk et al, 2000) . MiR-17B92 miRNAs were significantly induced at the lymphoma stage, and this correlated with Myc expression ( Figure 3A and B). The deletion of miR-17B92 was confirmed in B cells of young Myc; miR fl/fl ;CD19Cre mice ( Figure 3B ), which exhibited largely normal B-cell development in the bone marrow and spleen ( Figure 3C ). We monitored a cohort of 31 Myc;miR fl/fl ; CD19Cre and 27 Myc;miR fl/fl mice over one and a half years for tumour development and survival ( Figure 3D ). Lymphoma-free survival of Myc;miR fl/fl ;CD19Cre mice was significantly extended.
We next performed phenotypic and molecular analyses of those lymphomas to gain insights into mechanisms underlying the delayed lymphoma development in Myc;miR fl/fl ; CD19Cre mice. Tumours in the control Myc;miR fl/fl group were predominantly mature and immature B-cell lymphomas, which are typical for l-Myc mice (Kovalchuk et al, 2000) ( Figure 4A and Supplementary Figure S3A ). In contrast, the vast majority of Myc;miR fl/fl ;CD19Cre lympho- Note that mouse no. 14 had FL in mesenteric lymph node and DLBCL on small intestine, and was counted in both the FL and DLBCL categories. Source data for this figure is available on the online supplementary information page.
mas were IgM À and expressed markers characteristic of (Welner et al, 2008) . These precursor B-cell lymphomas were found in only a small fraction of Myc;miR fl/fl mice ( Figure ;CD19Cre mice, the complete absence of miR-17B92 deletion was also observed. It is likely that these tumours were derived from the small fraction of B cells with insufficient amounts of Cre expression (Rickert et al, 1997) . Consistent with the presence of intact miR-17B92 alleles, lymphomas that ultimately developed in Myc;miR fl/fl ; CD19Cre mice displayed drastically induced miR-17B92 miRNAs expression, to the same degree as that in Myc;miR fl/fl lymphomas ( Figure 4D ). In addition, the c-Myc protein level was comparable between Myc;miR fl/fl ;CD19Cre and Myc;miR fl/fl lymphomas ( Figure 4E ). Thus, the delayed lymphoma development in Myc;miR fl/fl ;CD19Cre mice reflects that malignant transformation is restricted to CD19-negative early B-cell precursors, in which the activity of l-light chain regulatory elements and activation of the Myc transgene might be opportunistic or low, and to a small fraction of CD19-positive B-lineage cells with insufficient Cre expression. Taken together, these results highlight a stringent selection pressure to maintain intact miR-17B92 alleles in Mycdriven lymphoma cells and emphasize an essential role of miR-17B92 in Myc-mediated lymphomagenesis.
Identification of miR-17B92 target genes in B cells by PAR-CLIP
We next explored the molecular pathways through which miR-17B92 drives lymphomagenesis and evaluated the possibility of targeting these pathways to treat lymphomas harbouring miR-17B92 overexpression. We employed the recently developed PAR-CLIP method to examine the miR-17B92 targetome in human B cells immortalized by Epstein-Barr virus ( Figure 5A ) (Hafner et al, 2010; Skalsky et al, 2012). Data obtained from three Ago2 PAR-CLIP libraries were combined, yielding 3744 unique miR-17B92 binding sites. The majority (81.2%) of identified miR-17B92 binding sites were present in protein-coding genes, and the rest (18.8%) were present in intergenic regions. Of the binding sites identified in protein coding genes, 1.1% corresponded to 5 0 UTRs, 14.9% to coding sequences (CDS), 45.4% to 3 0 UTRs, and 19.8% to intronic regions ( Figure 5B ). Evolutionary conservation of miRNA-mRNA interactions, especially pairing at the seed region, has emerged as a major characteristic of miRNA-mediated gene regulation (Rajewsky, 2006; Bartel, 2009 ). Since miR-17B92 family miRNAs are highly conserved in vertebrates (Tanzer and Stadler, 2004) , we reasoned that their functionally important binding sites should be conserved between human and mouse. Among the 3744 miR-17B92 binding sites identified by Ago2 PAR-CLIP, 1139 sites were conserved in mouse (Supplementary  Table S3 ). Strikingly, about half of the CDS and 3 0 UTR sites were conserved, while the conservation rates for intronic and intergenic sites were only 6 and 8%, respectively, and only 6 of the 42 5 0 UTR sites were conserved. These findings suggest that miR-17B92 functions mainly through its binding sites in the CDS and 3 0 UTR regions of target mRNAs, and are in agreement with previously published PAR-CLIP results from HEK293 cells (Hafner et al, 2010) .
The 1139 conserved binding sites corresponded to 868 protein coding genes, including a few miR-17B92 targets previously validated in various cellular contexts (i.e. Bim, E2F3, Pten, and Tgfbr2) (Sylvestre et al, 2007; Xiao et al, 2008; Dews et al, 2010; Mestdagh et al, 2010; Jiang et al, 2011) . Pathway analysis using the Ingenuity software revealed that miR-17B92 targets are involved in a broad spectrum of biological processes and identified 'molecular mechanisms of cancer' as the most enriched pathway (Supplementary Figure S4) . From this category, we further narrowed down to a list of 18 target genes most likely implicated in lymphomagenesis based on published literatures, including those involved in cell cycle, apoptosis, nuclear factor kappa B (NFkB) pathway, phosphatidylinositol-3 kinase (PI3K) pathway, and transforming growth factor beta (TGFb pathway ( Figure 5C ). We speculate that miR-17B92 regulation of these genes underlies its role in lymphomagenesis.
Transgenic expression of miR-17B92 promotes B-cell proliferation and survival
We evaluated the impact of transgenic miR-17B92 expression on select target genes and pathways identified by PAR-CLIP. For this purpose, we purified naive follicular B cells (also known as B2 cells) from young and disease-free TG and control mice, stimulated them with anti-IgM, and examined the target gene protein levels and target pathway activities. In vitro activation is relevant in this case, because the majority of lymphomas developed in TG mice are DLBCL, FL, and AP, which are thought to originate from previously activated B (Figure 6B ), earlier appearance of phosphorylated Rb ( Figure 6D ) and increased percentage of live cells in the culture ( Figure 6C ). Accordingly, PAR-CLIP-identified target genes, such as cell cycle regulator E2F3 and proapoptotic protein Bim, showed significantly reduced protein levels in TG B2 cells during early stages of activation ( Figure 6D and E). We also examined the protein levels of E2F1 and E2F2, two E2F transcription family members that were previously shown to be miR-17B92 target genes in various cell culture systems (Sylvestre et al, 2007) . Their expression was not significantly affected by transgenic miR-17B92 expression ( Figure 6D ). We examined additional target genes of relevance, including Rb and Casp11, as identified by PAR-CLIP, but found no significant downregulation in their protein levels. This suggests the existence of another layer of regulation beyond miRNA-target mRNA interaction (see Discussion). The protein level of another PAR-CLIP-identified target, Cyclin D2 (Ccnd2), was initially increased but decreased at a later time point in TG B2 cells, possibly a consequence of altered proliferation of these cells ( Figure 6D ). Therefore, transgenic miR-17B92 expression suppresses the expression of E2F3 and Bim, and this may contribute to the enhanced proliferation and survival of TG B2 cells.
We next examined the TGFb signalling pathway in TG B2 cells. TGFb is a potent inhibitor of cell proliferation in the hematopoietic system. Resistance to TGFb develops during lymphomagenesis, often through decreased expression of TGFb receptors on the cell surface or repression of TGFb signalling by oncoproteins (Dong and Blobe, 2006) . Our PAR-CLIP analysis identified multiple components of the TGFb signalling pathway as miR-17B92 targets ( Figure 5C ). However, flow cytometry analysis of cell surface Tgfbr2 expression did not reveal any difference between TG and WT B2 cells (Supplementary Figure S5A) . Western blot analysis of the protein level of Trim33, a PAR-CLIP-identified miR-17B92 target and a key mediator of the Smad-independent TGFb signalling branch (He et al, 2006) , and Smad2 phosphorylation, an important step of the Smaddependent TGFb signalling branch, did not reveal any significant abnormality in TG B2 cells. Similarly, the protein levels of Smad4, another PAR-CLIP-identified target, are comparable in TG and WT B2 cells (Supplementary Figure  S5B) . These results suggest that transgenic miR-17B92 expression does not have a major impact on the TGFb signalling pathway. 
miR-17B92 enhances the NFjB and PI3K pathway activities by suppressing the expression of multiple negative regulators
Human lymphomas often activate multiple oncogenic pathways, and genetic alterations of genes in the NFkB and PI3K pathways are among the most frequently found mutations . Interestingly, our PAR-CLIP analysis identified multiple negative regulators of these two pathways as miR-17B92 target genes. Two miR-17B92 targets, Pten and Phlpp2, are key inhibitors of the PI3K signalling pathway (Supplementary Figure S6C) (O'Neill et al, 2012; Song et al, 2012) , and their expression was significantly repressed by transgenic miR-17B92 expression ( Figure 7A ). The phosphorylation of ribosomal protein S6, a direct readout of the PI3K pathway activity, was significantly increased in TG B2 cells. Consistent with previous reports that S6 kinases (S6Ks) and the phosphorylation of its substrate S6 are involved in determining cell size (Ruvinsky and Meyuhas, 2006) , TG B2 cells were significantly larger than their WT counterparts ( Figure 7B) . Therefore, transgenic miR-17B92 expression enhances the PI3K pathway activity by suppressing the expression of two negative regulators, Pten and Phlpp2.
NFkB signalling can be dichotomized into the canonical and alternative pathways (Oeckinghaus and Ghosh, 2009) . Two deubiquitinases, Cyld and the A20 ubiquitin-editing complex, downregulate the canonical NFkB pathway by removing pathway-activating K63-ubiquitin chains on key signalling molecules (Supplementary Figure S6C) (Harhaj and Dixit, 2011) . Remarkably, our PAR-CLIP analysis identified Cyld and three major subunits of the A20 ubiquitin-editing complex (A20, Rnf11, and Tax1bp1) as miR-17B92 target genes, and their protein levels were all significantly reduced in TG B2 cells ( Figure 7C ). The fourth major subunit of the A20 ubiquitin-editing complex, Itch, was previously identified as a miR-17B92 target gene in the PAR-CLIP analysis of HEK293 cell (Hafner et al, 2010) . Its expression was also decreased by transgenic miR-17B92 expression ( Figure 7C ). The downregulation of these negative regulators led to enhanced BCR-induced activation of the canonical NFkB pathway, as indicated by reduced IkBa and IkBb protein levels and increased nuclear NFkB activity in TG B2 cells (Figure 7C and D) . Our PAR-CLIP analysis also identified Traf3, a negative regulator of the alternative NFkB pathway, as a miR-17B92 target gene ( Figure 5C ). The protein level of Traf3 was significantly reduced in TG B2 cells, but this did not lead to an obvious increase in the activity of the alternative NFkB pathway (Supplementary Figure S6A and B) . Thus, transgenic miR-17B92 expression specifically enhances the canonical NFkB pathway activity.
Taken together, our analysis of PAR-CLIP-identified target genes and pathways in TG B2 cells demonstrated that transgenic miR-17B92 expression promotes cell survival and proliferation by suppressing the expression of multiple inhibitors of the PI3K (Pten and Phlpp2) and NFkB (Cyld, A20, Itch, Rnf11, and Tax1bp1) pathways, the pro-apoptotic protein Bim, and cell cycle regulator E2F3 (Supplementary Figure S6C) . The coordinated activation of these oncogenic pathways may eventually drive lymphomagenesis in TG mice.
Chemical inhibition of the PI3K and NFjB pathways prolonged the survival of mice bearing miR-17B92-driven lymphomas
We next analysed the status of NFkB and PI3K pathways in TG lymphomas. For this purpose, we utilized the lymphoma cells purified from Rag1
À / À -recipient mice transplanted with primary TG lymphomas. MiR-17B92 expression in those lymphoma cells is 3-11-fold higher than that in WT B cells, and is similar to those found in human lymphomas ( Figure 8A and B) (He et al, 2005; Schmitz et al, 2012) . Consistent with our findings that transgenic miR-17B92 expression promotes the activation of NFkB and PI3K pathways in TG B cells in young mice, all TG lymphomas analysed exhibit high levels of activities of both pathways ( Figure 8C and D). These results suggest that miR-17B92-mediated activation of these two pathways may play important roles in the maintenance of lymphoma cells, in addition to its function in driving lymphomagenesis. We explored the possibility of treating miR-17B92-driven lymphomas using chemical inhibitors of the PI3K and NFkB pathways. For this purpose, we transplanted TG lymphoma cells into Rag1 À / À mice and treated recipient mice with either PI3K pathway inhibitor AZD8055 (Chresta et al, 2010) or NFkB pathway inhibitor BMS-345541 (Burke et al, 2003) . Consistent with previous reports, molecular analysis of lymphoma cells from chemical inhibitor-treated mice showed that AZD8055 inhibited the phosphorylation of Akt and S6 (Supplementary Figure S7A) and reduced lymphoma cell size (Supplementary Figure S7B) , while BMS-345541 inhibited IkBa phosphorylation (Supplementary Figure S7C) and nuclear NFkB activity (Supplementary Figure S7D) . Figure 8 Constitutive NFkB and PI3K pathway activity in TG lymphoma cells. Primary TG lymphomas were transplanted into Rag1 À / À mice and CD19 þ lymphoma cells were purified from recipient mice B3 weeks post transplantation. (A) miR-17B92 expression was determined by northern blot. (B) Bar graph summarizes two independent northern blot experiments (n ¼ 5 for control B cells and 10 for lymphomas). miR/U6 ratio in freshly purified control B cells was set as 1. (C) Nuclear NFkB activity was determined by EMSA. Purified control B cells rested in B cell medium for 3 h (rested) or stimulated with 2 mg/ml anti-IgM for 24 h (24 h) were used as control. NFkB activity in rested B cells was set as 1. (D) The PI3K pathway activity was determined by western blot analysis of pS6. pS6/b-actin ratio in freshly purified control B cells was set as 1. Source data for this figure is available on the online supplementary information page.
Strikingly, both inhibitors significantly reduced tumour size and prolonged the survival of recipient mice ( Figure 9A-C) . Therefore, miR-17B92-driven lymphomas are addicted to the PI3K and NFkB pathways and targeting these pathways has therapeutic value in treating lymphomas harbouring miR-17B92 overexpression.
Discussion
The present study shows that elevated miR-17B92 expression is sufficient to drive lymphomagenesis and, conversely, miR-17B92 is essential for Myc-mediated lymphoma development. Our molecular analyses revealed that miR-17B92 drives lymphomagenesis by suppressing the expression of multiple inhibitors of the PI3K and NFkB pathways and by inhibiting the mitochondrial apoptosis pathway, that miR-17B92-driven lymphoma cells exhibit constitutive activation of the PI3K and NFkB pathways, and that chemical inhibition of these two pathways has therapeutic value in treating miR-17B92-driven lymphomas.
These findings firmly establish miR-17B92 as a powerful cancer driver, and therefore, a valid target for cancer therapeutics. This places miR-17B92 in the pantheon of prominent cancer genes that includes Myc, Ras, Pik3ca (p110a), Pten, and p53 (Schubbert et al, 2007; Liu et al, 2009; Olivier et al, 2010; Dang, 2012) . The ubiquitous nature of miR-17B92 gene amplification and overexpression in human cancers suggests that it plays important roles in other cancer types as well. This warrants a comprehensive investigation of miR-17B92 in additional cancer models in the future.
Our findings of the essential role of miR-17B92 in Mycmediated lymphomagenesis and the promotion of PI3K pathway activation by miR-17B92 are especially notable in the context of Burkitt lymphoma, which is characterized by Myc overexpression (Klapproth and Wirth, 2010) . Recent studies showed that miR-17B92 was drastically overexpressed and the PI3K pathway was constitutively active in a large number of Burkitt lymphoma patient biopsies (Schmitz et al, 2012) , and that combining Myc overexpression and constitutive PI3K pathway activation in germinal centre B cells of the mouse led to the development of lymphomas that are similar to human Burkitt lymphomas (Sander et al, 2012) . Considering these two studies together with ours, it becomes highly likely that the Myc -miR-17B92 B Pten/Phlpp2 B PI3K axis plays a fundamental role in Burkitt lymphomagenesis and may well be the Achilles' heel of this disease. It will be interesting to investigate in the future whether PI3K pathway inhibitors are effective in treating Myc-driven lymphomas.
While bioinfomatic algorithms have predicted thousands of potential target genes for miR-17B92 and a few of them (Bim, E2F1, E2F2, E2F3, p21, Pten, Rbl2, and Tgfbr2) were experimentally validated in various cellular contexts (O'Donnell et al, 2005; Lu et al, 2007; Sylvestre et al, 2007; Petrocca et al, 2008; Xiao et al, 2008; Dews et al, 2010; Mestdagh et al, 2010; Jiang et al, 2011) , it was unclear which ones of the predicted targets are direct targets and whether miR-17B92 regulates different sets of target genes in different cellular contexts. Our PAR-CLIP analysis identified 868 conserved target genes for miR-17B92, including a few previously validated targets (Bim, E2F3, Pten, and Tgfbr2). Although the PAR-CLIP experiments were performed in B cells, most identified miR-17B92 targets are broadly expressed genes, suggesting that miR-17B92 regulates a common set of target genes in different cell types. Some miR-17B92 target genes previously validated in other cellular systems (i.e., E2F1, E2F2, p21, and Rbl2) are absent from our PAR-CLIP target list, suggesting that miR-17B92 regulates additional cell type-specific target genes. The discovery and validation of those target genes awaits CLIP analysis of other cell types, as well as generation and analysis of animal models with miR-17B92 overexpressed or deleted specifically in the corresponding cell types.
Our validation of PAR-CLIP-identified target genes in miR-17B92 transgenic B cells led to the elucidation of molecular mechanisms underlying its role in lymphomagenesis. The most striking finding is that miR-17B92 suppresses the expression of multiple inhibitors of the PI3K and NFkB pathways. The PI3K pathway is perhaps the most commonly activated signalling pathway in human cancers. Activating mutations of Pik3ca (p110a), Pik3cb (p110b), Akt1, Akt2, Akt3, and deletion or loss-of-function mutations of Pten have been found in a broad spectrum of cancers including lymphomas (Liu et al, 2009) . Interestingly, deletion of Pten alone in B cells did not cause lymphoma in mice (Miletic et al, 2010) . We previously identified Pten as a miR-17B92 target gene and this was confirmed in our PAR-CLIP experiments (Xiao et al, 2008) . While the PI3K pathway activity was drastically increased in activated TG B cells, the reduction in the Pten protein level was relatively mild. This discrepancy was reconciled by the identification of another PI3K pathway inhibitor, Phlpp2, as a miR-17B92 target gene by PAR-CLIP. Phlpp2 was recently discovered to be the long-sought Akt phosphatase, and its expression is lost or decreased in a variety of cancers (O'Neill et al, 2012) . Consistent with a potentially critical role in mediating miR-17B92 regulation of the PI3K pathway, the Phlpp2 protein level was markedly reduced in TG B cells. Thus, elevated miR-17B92 expression enhances the PI3K pathway activity by suppressing the expression of two key negative regulators, Pten and Phlpp2.
The most commonly activated signalling pathway in human B-cell lymphomas is the NFkB pathway, which promotes the survival, activation, and proliferation of lymphocytes (Gerondakis and Siebenlist, 2010; Staudt, 2010) . Deletion and inactivating mutations of Cyld and A20 are recurrent events in human lymphomas. These, together with genetic alterations of other signalling components, lead to the activation of the canonical NFkB pathway in a large percentage of lymphoma cases (Staudt, 2010) . A recent study showed that constitutive activation of the canonical NFkB pathway in B cells, together with genetic ablation of Blimp1, a transcription factor essential for plasma cell differentiation, led to lymphoma development in the mutant mice (Calado et al, 2010) . Our study found that miR-17B92 enhances the canonical NFkB pathway activity by suppressing the expression of two major negative inhibitors of this pathway, Cyld and the A20 ubiquitin-editing complex (Harhaj and Dixit, 2011) . The regulation of the latter is remarkable in that miR-17B92 targets all four major subunits of the A20 complex (A20, Itch, Rnf11, and Tax1bp1). Given the frequent activation of the NFkB pathway in human lymphomas and their demonstrated oncogenic activity in mouse models, miR-17B92-mediated regulation of this pathway should play an important role in lymphomagenesis.
In addition to the identification of the PI3K and NFkB pathways as two major target pathways of miR-17B92, our study confirmed the previous findings that miR-17B92 suppresses the expression of pro-apoptotic protein Bim and cell cycle regulator E2F3. Genetic studies have shown that E2F3 plays a critical role in normal cellular proliferation of mouse embryonic fibroblasts (Humbert et al, 2000; Wu et al, 2001 ). Further investigation is necessary to determine what roles it may play in lymphocytes and in miR-17B92-driven lymphomagenesis. Members of the Bcl2 family are major regulators of the mitochondrial pathway of apoptosis in lymphocytes. Bim and Bcl2 associate with and antagonize each other (Rathmell and Thompson, 2002) . Bcl2 overexpression by translocation, gene amplification, and transcriptional upregulation is commonly found in lymphomas, especially in follicular lymphomas (Shaffer et al, 2012 ).
Homologous deletion of Bim was also found in mantle cell lymphomas (Tagawa et al, 2005) . Accordingly, B cell-specific transgenic expression of Bcl2 led to B-cell hyperplasia and the development of lymphoma in a small fraction of mutant mice at old ages (McDonnell and Korsmeyer, 1991) . In addition, both the Bcl2 transgene and heterozygous deletion of Bim drastically accelerated Myc-mediated lymphomagenesis in the Em-Myc transgenic mouse model (Strasser et al, 1990; Egle et al, 2004) . Therefore, suppression of Bim expression by miR-17B92 should contribute to its role in lymphomagenesis. Taken together, our PAR-CLIP analysis and targetgene validation in miR-17B92 transgenic B cells demonstrate that miR-17B92 coordinates the activation of multiple oncogenic pathways to drive lymphomagenesis (Supplementary Figure S6C ).
The functional importance of the PI3K and NFkB pathways was further examined in a lymphoma transplantation model. We showed that chemical inhibitors blocking either of these two pathways significantly controlled tumour growth and prolonged the survival of mice bearing miR-17B92-driven lymphomas. This demonstrates that miR-17B92-mediated activation of these two pathways plays important roles in both lymphoma development and maintenance, and targeting these pathways has therapeutic value in treating lymphomas harbouring miR-17B92 overexpression.
The present study combines target identification by PAR-CLIP and target validation in miRNA mutant animals for the first time, and sheds light on a few basic principles governing miRNA biology and the development of miRNA-based cancer therapeutics. First, our PAR-CLIP results show that the vast majority of evolutionarily conserved miRNA binding sites are found in 3 0 UTR and CDS of protein-coding genes. Some previous studies found miRNA-binding sites in 5 0 UTRs and intergenic regions, leading to the speculation that miRNAs can function through those sites (Lytle et al, 2007; Orom et al, 2008) . Our results indicate that miRNAs function mainly by regulating the expression of protein-coding genes through their cognate sites in 3 0 UTR and CDS. This is consistent with the recently published PAR-CLIP analysis of HEK293 cells (Hafner et al, 2010) . Second, most PAR-CLIP-identified miR-17B92 target genes contain only one conserved binding site for miRNAs encoded by this cluster. This observation could have profound implications in interpreting the results from previous studies of miRNA mechanisms of action. Very often those studies employed reporter constructs that contained multiple binding sites for the miRNA of interest. The impact of a miRNA on a reporter mRNA containing multiple closely located binding sites could be very different from that on an endogenous target mRNA with only one binding site, in terms of the relative contribution of translation repression and mRNA degradation, as well as the degree of repression on target protein levels (Huntzinger and Izaurralde, 2011) . Third, miRNA binding does not necessarily warrant functional consequence. MiR-17B92 regulation of Tgfbr2 is a case in point. Several independent studies showed that Tgfbr2 is a direct target of miR-17B92 and miR-17B92 suppresses Tgfbr2 expression in various cellular contexts. The PAR-CLIP analysis in this study also identified Tgfbr2 as a miR-17B92 target gene, with the same binding site as reported before Mestdagh et al, 2010; Jiang et al, 2011) . However, the surface expression of Tgfbr2, as well as TGFb-induced Smad2 phosphorylation, was identical between TG and WT B cells. This cellular context dependence suggests that an additional layer of regulation exists and governs the functional consequence of miRNA-target mRNA interactions. RNA-binding proteins may participate in this regulation, as suggested by a few recent studies (van Kouwenhove et al, 2011) . This emphasizes the importance of examining miRNA-target gene interactions in desired cells in animal models with gain-or loss-offunction mutations for miRNAs of interest. Fourth, this study confirms that a miRNA targets multiple components of functionally related pathways to generate a significant impact on the biological processes it regulates, as proposed by us and other investigators in previous publications (Krek et al, 2005; Xiao and Rajewsky, 2009) . A cluster of miRNAs with different seed sequences may have additional advantages in this context, because they can target several components in each pathway to achieve a synergistic effect. This may explain why a modest increase in miR-17B92 expression alone is sufficient to drive lymphomagenesis. Finally, this study shows that identification of cancer drivers and elucidation of their molecular mechanism of action are essential for the development of cancer therapeutics. The best-studied modality of miRNA-based therapy to date is to silence or replete cancer-related miRNAs using antisense miRNA inhibitors or miRNA mimics, respectively (van Rooij and Olson, 2012; Nana-Sinkam and Croce, 2013) . However, the safety and efficacy of using these oligonucleotide-based agents to treat human cancers remain to be tested. In contrast, small chemical compounds targeting miRNA downstream pathways have been developed and many of them are in clinical trials. Conceptually, chemical compounds targeting functionally important pathways controlled by miRNAs may be effective in treating miRNA-related diseases. A thorough understanding of molecular mechanisms underlying miRNA action would be essential for this approach to work. The present study demonstrates, for the first time to our knowledge, that the combination of experimental target-gene identification by PAR-CLIP and target validation in miRNA mutant animals is a solid way to elucidate molecular pathways controlled by miRNAs, and that chemical inhibition of these pathways has therapeutic value in treating cancers caused by miRNA dysregulation.
Materials and methods
Mice
The generation of miR-17B92 Tg (Jax stock 008517), miR-17B92 flox (Jax stock 008458), CD19Cre (Jax stock 006785), and l-Myc mice was previously reported (Rickert et al, 1997; Kovalchuk et al, 2000; Ventura et al, 2008; Xiao et al, 2008) . MiR-17B92 Tg mice were crossed with CD19Cre mice to generate miR-17B92 Tg/Tg; CD19Cre (TG) mice. miR-17B92 flox, CD19Cre, and l-Myc mice were crossed to generate l-Myc;miR-17B92 flox/flox;CD19Cre (Myc;miR fl/fl ;CD19Cre) and l-Myc;miR-17B92 flox/flox (Myc;miR fl/fl ) mice. Cohorts of mice were monitored for disease development for up to 2 years, and euthanized for analysis when they appeared sick. Littermate control mice were euthanized as experimental control and were counted as 'right-censored' data in the Kaplan-Meier survival analysis (Stel et al, 2011) . All animal experiments were approved by Animal Care and Use Committee of The Scripps Research Institute.
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